Skip to main content

Table 1 Demographic data, clinical characteristics and routine hematological and biochemical parameters of breast cancer patients and controls

From: Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability

  Control group (n = 30) All patients (n = 62) Localized stage (n = 13) Regional stage (n = 29) Metastatic stage (n = 20)
Age (year) 55 ± 10 52 ± 11 53 ± 10 54 ± 11 49 ± 13
BMI (Kg/m2) 27 ± 6 28 ± 4.7 29.6 ± 4.7 27.6 ± 4.2 27.7 ± 5.6
Hemoglobin (g/dL) 11.6 ± 2 11.5 ± 1.5 11.2 ± 1.1 11.8 ± 1.4 11.3 ± 1.8
Leukocytes (109/L) 7.3 ± 1.8 7.1 ± 4.8 7.2 ± 2.4 7.1 ± 2.8 7.1 ± 5
Platelets (109/L) 270 ± 62 242 ± 96 262 ± 65 264 ± 98 198 ± 98
PT (% of prothrombin) 100 ± 8 92 ± 8.3 94 ± 6 95 ± 7 89 ± 11
aPTT ratio 1 ± 0.2 0.9 ± 0.06 0.9 ± 0.05 0.9 ± 0.06 0.9 ± 0.08
Fibrinogen (g/L) 3.9 ± 0.6 4.4 ± 1.2 4 ± 0.8 4.7 ± 1.4 4.4 ± 1.1
CRP (mg/L) - 14.5 ± 50 32 ± 99 7 ± 20 10 ± 15
ALAT (IU/L) - 25 ± 13 30 ± 16 24 ± 10 25 ± 15
ASAT (IU/L) - 36 ± 23 31 ± 18 34 ± 17 43 ± 32
Creatinine (μmol/L) - 65 ± 17 67 ± 23 67 ± 17 62 ± 13
Urea (mg/dL) - 5 ± 2 5 ± 1.6 5.5 ± 2.7 5 ± 2.2
Time since diagnosis (n)      
0-6 months   27 8 15 4
6-12 months   10 2 7 1
12-36 months - 13 3 5 5
> 36 months   12 0 2 10
Cardiovascular risk factors (n)      
-Hypertension no 14 3 9 2
-Varicose veine no 8 1 6 1
-Hyperlipidemia no 4 1 3 0
-Diabetes no 6 1 3 2
  1. Data are presented as mean ± sd.